Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Масштабируемое полное экзомное секвенирование внеклеточной ДНК выявляет высокую конкордантность с метастатическими опухолями
2017-10-31
SCID: 54.1/f6nhr4gz
Discuss with AI
cell-free DNAcopy number alterationsichorCNAmetastatic tumorswhole-exome sequencing
Figures from the paper
Abstract (AI)
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.
Key Findings
1
Among 520 patients with metastatic prostate or breast cancer, 34% had at least 10% tumor-derived cfDNA in their earliest sample.
2
At least 10% cfDNA tumor content enabled standard-coverage whole-exome sequencing for comprehensive tumor profiling.
3
Mutational signatures and neoantigens were also concordant between cfDNA and matched tumor biopsies, supporting broad applicability of cfDNA whole-exome sequencing.
4
cfDNA and matched metastatic tumor biopsies showed concordance of 88% for clonal somatic mutations and 80% for copy-number alterations.
5
ichorCNA quantifies tumor content in cfDNA using 0.1× whole-genome sequencing without prior knowledge of tumor mutations.
Research Object
cell-free DNA and matched metastatic tumor biopsies from patients with metastatic prostate or breast cancer
Research Subject
genome-wide concordance of whole-exome profiles, including clonal somatic mutations, copy-number alterations, mutational signatures, and neoantigens
Publication Details
Publication Date
2017-10-31
Journal
Publisher
ISSN
Cited by
1055
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest